Evidence map›Paper›PMID 31155227›Full record

ReviewSeminars in immunology2019

Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Sabelo Lukhele, Giselle M Boukhaled, David G Brooks

Registry-linked trialAbstract readReview
In one paragraph

Review in Seminars in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07527247 (Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity), which is not on this map. Cited by 106 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07527247 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity

TypeinterventionalSponsorSingapore General HospitalRan2025 to 2029Enrolled40ConditionsImmune System Responses and Trained Immunity After AS01 Administration, Healthy AdultArmsAS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL)
3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Transcriptional insights into the CD8Journal of translational medicine · 2020
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Immune system expression profiling in patients experiencing low back pain: A pilot study.PM & R : the journal of injury, function, and rehabilitation · 2026
    Observational
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Immunology of RNA-based vaccines: The critical interplay between inflammation and expression.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sabelo LukhelePrincess Margaret Cancer Center, Tumor Immunotherapy Program, University Health Network, Toronto, Ontario, M5G 2M9, Canada.
Giselle M BoukhaledPrincess Margaret Cancer Center, Tumor Immunotherapy Program, University Health Network, Toronto, Ontario, M5G 2M9, Canada.
David G BrooksPrincess Margaret Cancer Center, Tumor Immunotherapy Program, University Health Network, Toronto, Ontario, M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada. Electronic address: dbrooks@uhnresearch.ca.

Funding

Mechanisms of Viral PersistenceR01AI085043 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BROOKS, DAVID G · 2010 to 2023
$4.5M
CIHR FDN148386NIAID NIH HHS R01 AI085043
6 · The paper itself

Abstract

Type I Interferons (IFN-I) mediate numerous immune interactions during viral infections, from the establishment of an antiviral state to invoking and regulating innate and adaptive immune cells that eliminate infection. While continuous IFN-I signaling plays critical roles in limiting virus replication during both acute and chronic infections, sustained IFN-I signaling also leads to chronic immune activation, inflammation and, consequently, immune exhaustion and dysfunction. Thus, an understanding of the balance between the desirable and deleterious effects of chronic IFN-I signaling will inform our quest for IFN-based therapies for chronic viral infections as well as other chronic diseases, including cancer. As such the factors involved in induction, propagation and regulation of IFN-I signaling, from the initial sensing of viral nucleotides within the cell to regulatory downstream signaling factors and resulting IFN-stimulated genes (ISGs) have received significant research attention. This review summarizes recent work on IFN-I signaling in chronic infections, and provides an update on therapeutic approaches being considered to counter such infections.

Indexed as

AnimalsChronic DiseaseGene Expression RegulationHumansImmunityInflammationInterferon Regulatory FactorsInterferon Type ISignal TransductionT-LymphocytesTranscriptional ActivationVirus DiseasesInterferon Regulatory FactorsInterferon Type IAdaptive immunityChronic virus infectionExhaustionImmune responseInnate immunityInterferonInterferon regulatory factorInterferon stimulatory geneIRFISGT cell

Identifiers

PMID31155227
PMCPMC8029807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.